Zobrazeno 1 - 10
of 25
pro vyhledávání: '"J L Pérez-Calle"'
Autor:
M Chaparro, D Acosta, C Rodríguez, F Mesonero, M Vicuña, M Barreiro-de Acosta, A Fernández-Clotet, Á Hernández Martínez, M Arroyo, I Vera, A Ruiz-Cerulla, B Sicilia, M J Cabello Tapia, C Muñoz Villafranca, J Castro-Poceiro, J Martínez Cadilla, M Sierra-Ausín, J M Vázquez Morón, E Montil Miguel, F Bermejo, V Royo, M Calafat, C González-Muñoza, E Leo Carnerero, N Manceñido Marcos, L Torrealba, H Alonso-Galán, J M Benítez, Y Ber Nieto, M T Diz-Lois Palomares, M J García, J F Muñoz, E M Armesto González, X Calvet, A Hernández-Camba, R E Madrigal Domínguez, L Menchén, J L Pérez Calle, M Piqueras, J P Gisbert
Publikováno v:
Journal of Crohn's and Colitis. 17:i806-i808
Background Main aim: To assess the durability of tofacitinib treatment in patients with ulcerative colitis (UC). Secondary aims: To assess the short and long-term effectiveness; the tolerability of tofacitinib in clinical practice; and to evaluate th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::592845492cf6ce9454ce40638b4aaa99
https://doi.org/10.1093/ecco-jcc/jjac190.0805
https://doi.org/10.1093/ecco-jcc/jjac190.0805
Autor:
M Chaparro, D Acosta, C Rodríguez, M Vicuña, F Mesonero, M Barreiro-de Acosta, A Fernández-Clotet, Á Hernández Martínez, M T Arroyo, I Vera Mendoza, B Sicilia, C Muñoz Villafranca, J Castro-Poceiro, J Martínez Cadilla, J M Vázquez Morón, E Montil, M Sierra-Ausín, M Calafat, E Leo Carnerero, N Manceñido Marcos, L Torrealba M, H Alonso-Galán, J M Benítez, Y Ber Nieto, M J Cabello Tapia, M T Diz-Lois Palomares, M J García, E M Armesto González, X Calvet Calvo, M Piqueras, C Dueñas Sadornil, J L Pérez Calle, B Botella, T D J Martínez-Pérez, L Ramos, M C Rodríguez-Grau, J L Fernández Forcelledo, A Gutiérrez, E Sesé Abizanda, J P Gisbert
Publikováno v:
Journal of Crohn's and Colitis. 16:i375-i377
Background Main aim: To assess the retention rate of tofacitinib treatment in patients with ulcerative colitis (UC). Secondary aims: To assess the short-term effectiveness and the durability of response; to evaluate the evolution of extraintestinal m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9c2067054ede194b5d2e0f136d83543d
https://doi.org/10.1093/ecco-jcc/jjab232.500
https://doi.org/10.1093/ecco-jcc/jjab232.500
Autor:
I Guerra Marina, F Barros, M Chaparro, J M Benítez, M D Martín Arranz, R de Francisco, M Piqueras, L de Castro, A Y Carbajo, F Bermejo, M Mínguez, A Gutiérrez, F Mesonero, F Cañete, C González-Muñoza, M Calvo, B Sicilia, E Alfambra, C A Tardillo, M Rivero, A J Lucendo, L Bujanda, M Van Domselaar, P Almela, L Ramos, M Fernández Sánchez, E Hinojosa, C Verdejo, A Gimenez, I Rodríguez-Lago, N Manceñido, J L Pérez Calle, M D P Moreno, P G Delgado-Guillena, B Antolín, P Ramírez de la Piscina, M J Casanova, Á Carracedo, E Domènech, J P Gisbert
Publikováno v:
Journal of Crohn's and Colitis. 17:i1018-i1019
Background Treatment with thiopurines may be associated with different adverse effects, including acute pancreatitis. Risk factors for developing pancreatitis due to thiopurines in patients with Inflammatory Bowel Disease (IBD) are not clearly identi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2d90e0b599cba979a0207044c716a2e5
https://doi.org/10.1093/ecco-jcc/jjac190.1035
https://doi.org/10.1093/ecco-jcc/jjac190.1035
Autor:
I Guerra Marina, F Barros, F Mesonero, R de Francisco, F Cañete, J M Benítez, B Sicilia, M D Martín Arranz, L de Castro, A Y Carbajo, A Gutiérrez, M Calvo, M J Casanova, C González-Muñoza, M Miguel, E Alfambra, M Rivero, A J Lucendo, C A Tardillo, P Almela, L Bujanda, M Van Domselaar, L Ramos, M Fernández Sánchez, E Hinojosa, C Verdejo, A Gimenez, M Piqueras, I Rodríguez-Lago, N Manceñido, J L Pérez Calle, M D P Moreno, P G Delgado, B Antolín, P Ramírez de la Piscina, F Bermejo, Á Carracedo, E Domènech, J P Gisbert
Publikováno v:
Journal of Crohn's and Colitis. 17:i668-i668
Background Treatment with thiopurines in patients with Inflammatory Bowel Disease (IBD) may be associated with different adverse effects, including acute pancreatitis. Our aims were to evaluate the clinical presentation, severity and management of ac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::90156aacebaa5a0afe31de775ac4782e
https://doi.org/10.1093/ecco-jcc/jjac190.0671
https://doi.org/10.1093/ecco-jcc/jjac190.0671
Autor:
David Olivares, Pilar Martínez-Montiel, B. Casis, J L Pérez Calle, Mario Calvo, Patricia Vega, Isabel Vera, A M Fuentes Coronel, R. Ferreiro, Cristina Alba, C. Taxonera Samsó, Rufo Lorente, M T Diz-Lois, M. Barreiro-de-Acosta
Publikováno v:
Journal of Crohn's and Colitis. 15:S374-S376
Background Adalimumab (ADA) dose escalation from 40 mg SC every other week (EOW) to 40 mg weekly is approved for IBD patients with loss of response. A recently registered device containing 80 mg of ADA will allow an alternative dose escalation regime
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7b3a8ba727ba9485d0d57653fde91c07
https://doi.org/10.1093/ecco-jcc/jjab076.479
https://doi.org/10.1093/ecco-jcc/jjab076.479
Publikováno v:
Revista Espanola de Enfermedades Digestivas, Vol 102, Iss 2, Pp 86-89 (2010)
Background: pulse oximetry is a widely accepted procedure for ventilatory monitoring during gastrointestinal endoscopy, but this method provides an indirect measurement of the respiratory function. In addition, detection of abnormal ventilatory activ
Externí odkaz:
https://doaj.org/article/1e0bc5dd346e4ff397bb33612147a324
Autor:
P. López-Serrano, J. L. Pérez-Calle, E. Carrera-Alonso, T. Pérez-Fernández, G. Rodríguez-Caravaca, D. Boixeda-de-Miguel, C. M. Fernández-Rodríguez
Publikováno v:
Revista Espanola de Enfermedades Digestivas, Vol 101, Iss 11, Pp 768-772 (2009)
Introduction: the incidence of inflammatory bowel disease (IBD) varies widely according to geographical area and has been reported to have increased in the last few years. No data are available on the current incidence of this disease in Madrid (Spai
Externí odkaz:
https://doaj.org/article/e59c91d5afc545ec9f6c68f2b3c3114a
Autor:
M Chaparro, A Garre, M Iborra, M Sierra, M Barreiro-de Acosta, A Fernández-Clotet, L de Castro, M Boscá-Watts, M J Casanova, A López-García, R Lorente, C Rodríguez, A Y Carbajo, M T Arroyo, A Gutiérrez, J Hinojosa, T Martínez-Pérez, A Villoria, F Bermejo, D Busquets, B Camps, F Cañete, N Manceñido, D Monfort, M Navarro-Llavat, J L Pérez-Calle, L Ramos, M Rivero, T Angueira, P Camo, D Carpio, I García-de-la-Filia, C González-Muñoza, L Hernández, J M Huguet, V J Morales, B Sicilia, P Vega, E Domènech, J P Gisbert
Publikováno v:
Journal of Crohn's & Colitis
Background The development program (UNIFI) has shown promising results of ustekinumab in ulcerative colitis (UC) treatment that should be confirmed in clinical practice. Aims Primary: to evaluate the durability of ustekinumab treatment in UC patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b02dbc447088806bfe5ea720e11aa4f8
http://europepmc.org/articles/PMC8194679
http://europepmc.org/articles/PMC8194679
Autor:
M Enriquez Rodriguez, Ollero Pena, A. Echarri Piudo, B Botella Mateu, D Martín Rodriguez, R Fraga Iriso, N. Manceñido Marcos, M I Calvo Moya, J L Pérez Calle, P Nos Mateu, G Molina Arriero, B Castro Senosiain, M. Pérez, M Sierra Ausín
Publikováno v:
Journal of Crohn's and Colitis. 14:S213-S214
Background One of the aims of the Spanish Working Group on inflammatory bowel disease IBD (GETECCU), is to improve the quality of life of their patients. Quality standards for IBD Units include educational and care support of IBD patients. A trained
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0335f9ee1e207d8103e0d3cb5c299c68
https://doi.org/10.1093/ecco-jcc/jjz203.281
https://doi.org/10.1093/ecco-jcc/jjz203.281
Autor:
M Chaparro, A Garre, M Iborra, M Barreiro-de Acosta, M J Casanova, L De Castro, A Fernández-Clotet, J Hinojosa, M Boscá-Watts, D Busquets, A López-García, R Lorente, N Manceñido, T Martínez, D Monfort, J L Pérez-Calle, A Villoria, T Angueira, F Bermejo, A Y Carbajo, D Carpio, C González-Muñoza, F Gomollón, J M Huguet, M Rivero, E Iglesias-Flores, M Sierra, L Hernández-Villalba, E Domènech, J P Gisbert
Publikováno v:
Journal of Crohn's and Colitis. 14:S394-S395
Background Ustekinumab has shown promising results in ulcerative colitis (UC) in the development program (UNIFI) that should be confirmed in clinical practice. Our aim was to evaluate the effectiveness and safety of ustekinumab in UC in real life. Me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::92b7c5da1329a6fe44024521905330fe
https://doi.org/10.1093/ecco-jcc/jjz203.563
https://doi.org/10.1093/ecco-jcc/jjz203.563